PMID- 36042712
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220906
IS  - 1178-6965 (Print)
IS  - 1178-6965 (Electronic)
IS  - 1178-6965 (Linking)
VI  - 15
DP  - 2022
TI  - A Comparison of the Effectiveness of Asthma Medications on Asthma Exacerbations 
      in Real World National Cohort.
PG  - 1155-1165
LID - 10.2147/JAA.S379394 [doi]
AB  - BACKGROUND: Although a wide variety of asthma medications have been developed and 
      are used in clinical practice, there is limited evidence of their comparative 
      effects on asthma exacerbations. METHODS: We used claims data provided by the 
      Health Insurance Review and Assessment Service. We selected subjects commencing 
      asthma treatment between July 1, 2017 and June 30, 2018, with no change in drug 
      regimen. The primary outcome was asthma exacerbation requiring systemic 
      corticosteroids. Cox regression analysis was used to assess outcomes considering 
      the exacerbation-free period. RESULTS: Of the 254,951 asthma subjects, 107,694 
      subjects (42.2%) experienced asthma exacerbation. Inhaled corticosteroids (ICSs) 
      (hazard ratio [HR], 0.378-0.508), ICS-long-acting beta (2)-agonist (LABAs) (HR, 
      0.284-0.479), long-acting muscarine antagonists (LAMAs) (HR, 0.432-0.572), 
      leukotriene receptor antagonists (LTRAs) (HR, 0.371-0.419), and xanthines (HR, 
      0.326-0.482) significantly reduced the rate of first and second exacerbation of 
      asthma (all P-values, <0.001). The clinical effectiveness of asthma medications 
      varied according to the active ingredient (HR 0.164-0.670) and was significant 
      for all active ingredients (all P-values, <0.001). The effectiveness of 
      combination treatment using ICS-LABA and LTRA varied (HR, 0.159-0.670); however, 
      all combination treatment options evaluated were effective in preventing asthma 
      exacerbations (all P-values, <0.001). Long-term use of ICS-LABA (HR, 
      0.278-0.653), LTRA (HR, 0.259-0.628), and xanthines (HR, 0.351-0.783) showed 
      consistent effectiveness (all P-values, <0.001). CONCLUSION: This real-world 
      study showed that the effectiveness of asthma medications varied according to 
      drug type, active ingredient, combination, and period of use, although 
      effectiveness was significant in all cases studied.
CI  - (c) 2022 Park et al.
FAU - Park, Hye Jung
AU  - Park HJ
AUID- ORCID: 0000-0002-1862-1003
AD  - Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Jeon, Soyoung
AU  - Jeon S
AUID- ORCID: 0000-0002-9916-1917
AD  - Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Lee, Hye Sun
AU  - Lee HS
AUID- ORCID: 0000-0001-6328-6948
AD  - Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Kim, Bo Yeon
AU  - Kim BY
AD  - Healthcare Insurance Review & Assessment Service, Wonju, Republic of Korea.
FAU - Chae, Yu Jin
AU  - Chae YJ
AD  - Healthcare Insurance Review & Assessment Service, Wonju, Republic of Korea.
FAU - Kim, Gui Ok
AU  - Kim GO
AD  - Healthcare Insurance Review & Assessment Service, Wonju, Republic of Korea.
FAU - Park, Jung-Won
AU  - Park JW
AD  - Division of Allergy and Immunology, Department of Internal Medicine, Yonsei 
      University College of Medicine, Seoul, Republic of Korea.
AD  - Institute of Allergy, Yonsei University College of Medicine, Seoul, Republic of 
      Korea.
FAU - Lee, Jae-Hyun
AU  - Lee JH
AUID- ORCID: 0000-0002-0760-0071
AD  - Division of Allergy and Immunology, Department of Internal Medicine, Yonsei 
      University College of Medicine, Seoul, Republic of Korea.
AD  - Institute of Allergy, Yonsei University College of Medicine, Seoul, Republic of 
      Korea.
LA  - eng
PT  - Journal Article
DEP - 20220824
PL  - New Zealand
TA  - J Asthma Allergy
JT  - Journal of asthma and allergy
JID - 101543450
PMC - PMC9420439
OTO - NOTNLM
OT  - asthma
OT  - combination
OT  - drug
OT  - exacerbation
OT  - medication
OT  - real-world data
COIS- The authors declare that they have no conflicts of interest in relation to this 
      work.
EDAT- 2022/09/01 06:00
MHDA- 2022/09/01 06:01
PMCR- 2022/08/24
CRDT- 2022/08/31 01:53
PHST- 2022/06/21 00:00 [received]
PHST- 2022/08/08 00:00 [accepted]
PHST- 2022/08/31 01:53 [entrez]
PHST- 2022/09/01 06:00 [pubmed]
PHST- 2022/09/01 06:01 [medline]
PHST- 2022/08/24 00:00 [pmc-release]
AID - 379394 [pii]
AID - 10.2147/JAA.S379394 [doi]
PST - epublish
SO  - J Asthma Allergy. 2022 Aug 24;15:1155-1165. doi: 10.2147/JAA.S379394. eCollection 
      2022.